IRIDEX CORP (IRIX) Form 10-Q — Aug 18, 2026
IRIDEX reported Q2 FY2026 revenue of $12.6 million, down 7.4% from $13.6 million a year earlier, as retina product sales fell 19.4% and only partially offset by 19.0% growth in the Cyclo G6 glaucoma line. Quarterly net loss widened to $1.3 million ($0.07 per share) from $1.0 million in the prior-year quarter. Gross margin slipped to 34.2% from 34.5%, which management attributed to higher manufacturing costs and tariff-related product cost increases during its transition to lower-cost contract manufacturers. Cost discipline continued — G&A fell 16.9% — and the six-month net loss narrowed to $1.8 million from $2.7 million.
Key figures
- Revenue
- 12566000
- Total Debt
- 4000000
- Debt Amount
- 4000000
- Revenue Yoy
- -7.4% (Q2 FY2026 vs. prior-year quarter; -4.3% for six months)
- Total Assets
- 27258000
- Cash Position
- 4680000
- Interest Rate
- 12
- Maturity Date
- 2028
- Shares Outstanding
- 17564912
- Q2 gross margin
- 34.2% (down from 34.5%)
- Working capital
- 10800000
- Six month revenue
- 24365000
- Accumulated deficit
- 94200000
- Six month gross margin
- 37.1% (down from 38.2%)
- Retina revenue change q2
- -19.4%
- Cyclo g6 revenue change q2
- +19.0%
- Novel growth notes undrawn
- 10000000
- Topcon revenue concentration
- 33% of Q2 revenue; 30% of six-month revenue
- Series b preferred outstanding
- 600,000 shares ($6.0M at $10.00/share)
Price after filing
Close on the filing date to close N calendar days later (from $0.86). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.